Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director · See Remarks | August 03, 2026 | August 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date August 03, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 717,203 |
Reported balance
After 2026-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-03 · Sale · Disposed 4,375 · Balance 717,203 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 25,410 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,410 F4: The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 25,410 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 25,410 F5: The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 124,956 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 124,956 F7: The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy LLC | 57,358 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 57,358 F6: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
F4: The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F5: The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F6: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F7: The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2022 Filed Jan 7, 2022 21:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 300 | $22.40 | $6,720.00 |
DisclosureSEC source: 0001567619-22-000851 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,479 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 21:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,000 | $1.68 | $1,680.60 |
DisclosureSEC source: 0001567619-22-000851 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 23:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-021900 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,635 Underlying: Common Stock · 1,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 23:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $17.00 | $17,000.00 |
DisclosureSEC source: 0001567619-21-021900 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,779 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 23:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,000 | $1.68 | $1,680.60 |
DisclosureSEC source: 0001567619-21-021900 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:19 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-019584 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,635 Underlying: Common Stock · 1,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:19 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $21.50 | $21,501.60 |
DisclosureSEC source: 0001567619-21-019584 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,779 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $21.35 to $21.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:19 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,000 | $1.68 | $1,680.60 |
DisclosureSEC source: 0001567619-21-019584 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 20:05 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-018022 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,635 Underlying: Common Stock · 2,500 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 20:05 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,500 | $24.92 | $62,293.50 |
DisclosureSEC source: 0001567619-21-018022 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,779 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $24.51 to $25.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 20:05 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,500 | $1.68 | $4,201.50 |
DisclosureSEC source: 0001567619-21-018022 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 18:10 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-017895 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,135 Underlying: Common Stock · 1,500 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 18:10 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,500 | $25.01 | $37,510.05 |
DisclosureSEC source: 0001567619-21-017895 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,779 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $25.00 to $25.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 18:10 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,500 | $1.68 | $2,520.90 |
DisclosureSEC source: 0001567619-21-017895 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-016925 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,635 Underlying: Common Stock · 1,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $21.14 | $21,137.00 |
DisclosureSEC source: 0001567619-21-016925 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,779 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $21.00 to $21.47, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,000 | $1.68 | $1,680.60 |
DisclosureSEC source: 0001567619-21-016925 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 22:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-014784 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,635 Underlying: Common Stock · 1,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 22:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,000 | $20.81 | $20,810.00 |
DisclosureSEC source: 0001567619-21-014784 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,779 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 22:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,000 | $1.68 | $1,680.60 |
DisclosureSEC source: 0001567619-21-014784 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,750 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-013157 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,635 Underlying: Common Stock · 1,750 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,750 | $26.58 | $46,515.00 |
DisclosureSEC source: 0001567619-21-013157 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,779 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,750 | $1.68 | $2,941.05 |
DisclosureSEC source: 0001567619-21-013157 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:35 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | OtherCommon Stock | 7,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012499 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 57,358 F1 · kind: Pro rata in-kind distribution from West Southwest Ventures LLC for no consideration. F2 · ownership.nature: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:35 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,750 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-011902 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,385 Underlying: Common Stock · 1,750 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:35 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,750 | $26.35 | $46,112.50 |
DisclosureSEC source: 0001567619-21-011902 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,779 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F3 · balance_after: Includes 1,006 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2021. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:35 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,750 | $1.68 | $2,941.05 |
DisclosureSEC source: 0001567619-21-011902 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F3 · balance_after: Includes 1,006 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2021. Read SEC document |
| May 07, 2021 Filed May 11, 2021 15:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-009502 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,135 Underlying: Common Stock · 750 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| May 07, 2021 Filed May 11, 2021 15:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 750 | $35.00 | $26,250.00 |
DisclosureSEC source: 0001567619-21-009502 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,773 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| May 07, 2021 Filed May 11, 2021 15:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 750 | $1.68 | $1,260.45 |
DisclosureSEC source: 0001567619-21-009502 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| May 05, 2021 Filed May 7, 2021 15:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,607 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-009257 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,885 Underlying: Common Stock · 1,607 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| May 05, 2021 Filed May 7, 2021 15:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,750 | $34.00 | $59,500.00 |
DisclosureSEC source: 0001567619-21-009257 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,773 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| May 05, 2021 Filed May 7, 2021 15:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,607 | $1.68 | $2,700.72 |
DisclosureSEC source: 0001567619-21-009257 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| April 30, 2021 Filed May 4, 2021 19:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,500 | $35.00 | $52,500.00 |
DisclosureSEC source: 0001567619-21-008942 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,916 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 21:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,750 | $29.93 | $52,377.50 |
DisclosureSEC source: 0001567619-21-007700 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,416 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| March 05, 2021 Filed Mar 5, 2021 20:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,750 | $30.55 | $53,462.50 |
DisclosureSEC source: 0001567619-21-005737 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,166 F3 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 54,450 RSUs. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 20:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 99,200 | $0.00 Strike: $32.44 | $0.00 |
DisclosureSEC source: 0001567619-21-005737 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,200 Underlying: Common Stock · 99,200 shares Expires 2031-03-03 F8 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 20:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 32,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-005737 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,916 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2022, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 54,450 RSUs. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,107 | $35.19 | $74,136.06 |
DisclosureSEC source: 0001567619-21-005545 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,216 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021. F2 · price: The transaction was executed in multiple trades in prices ranging from $35.12 to $35.385, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 21,750 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 21:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-002434 · doc1.xml · derivative · entry 8 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,492 Underlying: Common Stock · 10,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 21:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 6,700 | $34.61 | $231,898.39 |
DisclosureSEC source: 0001567619-21-002434 · doc1.xml · nonDerivative · entry 3 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,323 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $34.21 to $35.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 21:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,300 | $33.64 | $111,017.28 |
DisclosureSEC source: 0001567619-21-002434 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,023 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $33.16 to $34.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 21:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 10,000 | $1.68 | $16,806.00 |
DisclosureSEC source: 0001567619-21-002434 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 20:13 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-000712 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,492 Underlying: Common Stock · 10,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 20:13 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $28.08 | $280,754.00 |
DisclosureSEC source: 0001567619-21-000712 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,323 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $27.71 to $28.53, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 1,395 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 1,320 shares on May 31, 2020 and 75 shares on November 30, 2020. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 20:13 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 10,000 | $1.68 | $16,806.00 |
DisclosureSEC source: 0001567619-21-000712 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 1,395 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 1,320 shares on May 31, 2020 and 75 shares on November 30, 2020. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 01:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-017383 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,492 Underlying: Common Stock · 3,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 01:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,000 | $30.00 | $90,000.00 |
DisclosureSEC source: 0001567619-20-017383 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,928 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 01:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 3,000 | $1.68 | $5,041.80 |
DisclosureSEC source: 0001567619-20-017383 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 569,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 29, 2020 Filed Jan 7, 2021 19:39 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-000711 · doc1.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,492 Underlying: Common Stock · 3,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.